These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1893 related articles for article (PubMed ID: 20139221)

  • 21. Adenocarcinoma in situ and associated human papillomavirus type distribution observed in two clinical trials of a quadrivalent human papillomavirus vaccine.
    Ault KA; Joura EA; Kjaer SK; Iversen OE; Wheeler CM; Perez G; Brown DR; Koutsky LA; Garland SM; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Majewski S; Muñoz N; Sings HL; Harkins K; Rutkowski MA; Haupt RM; Garner EI;
    Int J Cancer; 2011 Mar; 128(6):1344-53. PubMed ID: 20949623
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
    MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of HPV-16/18 AS04-adjuvanted vaccine on preventing subsequent infection and disease after excision treatment: post-hoc analysis from a randomized controlled trial.
    Zhao S; Hu S; Xu X; Zhang X; Pan Q; Chen F; Zhao F
    BMC Infect Dis; 2020 Nov; 20(1):846. PubMed ID: 33198657
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States.
    Wheeler CM; Hunt WC; Joste NE; Key CR; Quint WG; Castle PE
    J Natl Cancer Inst; 2009 Apr; 101(7):475-87. PubMed ID: 19318628
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data.
    Joura EA; Garland SM; Paavonen J; Ferris DG; Perez G; Ault KA; Huh WK; Sings HL; James MK; Haupt RM;
    BMJ; 2012 Mar; 344():e1401. PubMed ID: 22454089
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Spectrum of genital human papillomavirus infection in a female adolescent population.
    Jamison JH; Kaplan DW; Hamman R; Eagar R; Beach R; Douglas JM
    Sex Transm Dis; 1995; 22(4):236-43. PubMed ID: 7482107
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial.
    Huh WK; Joura EA; Giuliano AR; Iversen OE; de Andrade RP; Ault KA; Bartholomew D; Cestero RM; Fedrizzi EN; Hirschberg AL; Mayrand MH; Ruiz-Sternberg AM; Stapleton JT; Wiley DJ; Ferenczy A; Kurman R; Ronnett BM; Stoler MH; Cuzick J; Garland SM; Kjaer SK; Bautista OM; Haupt R; Moeller E; Ritter M; Roberts CC; Shields C; Luxembourg A
    Lancet; 2017 Nov; 390(10108):2143-2159. PubMed ID: 28886907
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection.
    Haupt RM; Wheeler CM; Brown DR; Garland SM; Ferris DG; Paavonen JA; Lehtinen MO; Steben M; Joura EA; Giacoletti KE; Radley DR; James MK; Saah AJ; Sings HL;
    Int J Cancer; 2011 Dec; 129(11):2632-42. PubMed ID: 21491420
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of Germany's human papillomavirus immunization program on HPV-related anogenital diseases: a retrospective analysis of claims data from statutory health insurances.
    Goodman E; Reuschenbach M; Viering T; Luzak A; Greiner W; Hampl M; Jacob C
    Arch Gynecol Obstet; 2024 Nov; 310(5):2639-2646. PubMed ID: 39230793
    [TBL] [Abstract][Full Text] [Related]  

  • 30. No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors.
    Woestenberg PJ; King AJ; van der Sande MA; Donken R; Leussink S; van der Klis FR; Hoebe CJ; Bogaards JA; van Benthem BH; ;
    J Infect; 2017 Apr; 74(4):393-400. PubMed ID: 28126492
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis.
    Drolet M; Bénard É; Pérez N; Brisson M;
    Lancet; 2019 Aug; 394(10197):497-509. PubMed ID: 31255301
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years.
    Wheeler CM; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Joura EA; Kurman RJ; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Lupinacci LC; Giacoletti KE; James M; Vuocolo S; Hesley TM; Barr E
    J Infect Dis; 2009 Apr; 199(7):936-44. PubMed ID: 19236277
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human papillomavirus quadrivalent vaccine: a look behind the numbers.
    Flaherty DK; Alkhateeb FM
    Ann Pharmacother; 2009 Apr; 43(4):740-4. PubMed ID: 19276314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of a quadrivalent human papillomavirus (types 6, 11, 16, 18) virus-like particle vaccine in European women aged 16 to 24.
    Majewski S; Bosch FX; Dillner J; Iversen OE; Kjaer SK; Muñoz N; Olsson SE; Paavonen J; Sigurdsson K; Bryan J; Esser MT; Giacoletti K; James M; Taddeo F; Vuocolo S; Barr E
    J Eur Acad Dermatol Venereol; 2009 Oct; 23(10):1147-55. PubMed ID: 19453788
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
    Wheeler CM; Castellsagué X; Garland SM; Szarewski A; Paavonen J; Naud P; Salmerón J; Chow SN; Apter D; Kitchener H; Teixeira JC; Skinner SR; Jaisamrarn U; Limson G; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Harper DM; Huh W; Hardt K; Zahaf T; Descamps D; Struyf F; Dubin G; Lehtinen M;
    Lancet Oncol; 2012 Jan; 13(1):100-10. PubMed ID: 22075170
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials.
    Rambout L; Hopkins L; Hutton B; Fergusson D
    CMAJ; 2007 Aug; 177(5):469-79. PubMed ID: 17671238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Estimates of the timing of reductions in genital warts and high grade cervical intraepithelial neoplasia after onset of human papillomavirus (HPV) vaccination in the United States.
    Chesson HW; Ekwueme DU; Saraiya M; Dunne EF; Markowitz LE
    Vaccine; 2013 Aug; 31(37):3899-905. PubMed ID: 23820080
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of HPV vaccination in women reaching screening age in Italy.
    Carozzi FM; Ocello C; Burroni E; Faust H; Zappa M; Paci E; Iossa A; Bonanni P; Confortini M; Sani C
    J Clin Virol; 2016 Nov; 84():74-81. PubMed ID: 27728850
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence.
    Kjær SK; Frederiksen K; Munk C; Iftner T
    J Natl Cancer Inst; 2010 Oct; 102(19):1478-88. PubMed ID: 20841605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection.
    FUTURE II Study Group
    J Infect Dis; 2007 Nov; 196(10):1438-46. PubMed ID: 18008221
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 95.